A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC; British Journal Of Haematology, 2004, vol. 127, issue 2, p 165, ISSN 00071048. ISBN 00071048.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef